Replies to post #173460 on Biotech Values

[jq1234]

Insulin FoB wasn't the reason. Reason was slower growth of Victoza, introduction of generic Prandin.

NVO's massive (more than 100 slides) presentation today:

http://www.novonordisk.com/images/investors/investor_presentations/2014/IR_presentations/Q4_2013_Investor_presentation_Cph.pdf